Eloxx Pharmaceuticals Stock Current Valuation
Valuation analysis of Eloxx Pharmaceuticals helps investors to measure Eloxx Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Eloxx Pharmaceuticals Company Current Valuation Analysis
Eloxx Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Eloxx Pharmaceuticals Current Valuation | 30.28 M |
Most of Eloxx Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eloxx Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Eloxx Pharmaceuticals has a Current Valuation of 30.28 M. This is 99.79% lower than that of the Pharmaceuticals sector and 99.35% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.82% higher than that of the company.
Eloxx Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eloxx Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eloxx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eloxx Pharmaceuticals by comparing valuation metrics of similar companies.Eloxx Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Eloxx Fundamentals
| Return On Equity | -6.15 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 30.28 M | ||||
| Shares Outstanding | 2.75 M | ||||
| Shares Owned By Insiders | 0.59 % | ||||
| Shares Owned By Institutions | 37.06 % | ||||
| Number Of Shares Shorted | 21.48 K | ||||
| Price To Earning | (7.94) X | ||||
| Price To Book | 6.31 X | ||||
| EBITDA | (34.42 M) | ||||
| Net Income | (36.06 M) | ||||
| Cash And Equivalents | 30.05 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 13.38 M | ||||
| Current Ratio | 1.62 X | ||||
| Book Value Per Share | (7.46) X | ||||
| Cash Flow From Operations | (31.84 M) | ||||
| Short Ratio | 0.20 X | ||||
| Earnings Per Share | (12.93) X | ||||
| Target Price | 55.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 2.68 | ||||
| Market Capitalization | 14.86 M | ||||
| Total Asset | 21.12 M | ||||
| Retained Earnings | (274.39 M) | ||||
| Working Capital | (2.96 M) | ||||
| Current Asset | 3.84 M | ||||
| Current Liabilities | 840.05 K | ||||
| Z Score | -23.07 | ||||
| Net Asset | 21.12 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Eloxx Pink Sheet
If you are still planning to invest in Eloxx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eloxx Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |